**Appendix E. Table 3. Evidence Table for primary RLS: Bupropion**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Study Characteristics****and Design** | **Inclusion/Exclusion criteria** | **Participant Characteristics** | **Intervention (daily dose) /Comparator (daily dose)** | **Risk of bias and Applicability** |
| **Study ID****Bayard, 201125****Geographical Location**:USA**Funding source**: Academic**Study Design**:parallel design, fixed-dose**Duration**: 6 weeks | **Inclusion criteria**: * Patients also had an International Restless Legs Scale (IRLS) total score ≥15 and meet diagnostic criteria based on 4 screening questions

**Exclusion criteria**: * history of seizure disorder, alcoholism, suicidal history or ideation
* inability to return for 3- and 6-week assessment, no telephone access
* eating disorders
* age younger than 18
* pregnancy
* unwillingness or inability to discontinue current medications for the treatment of RLS.
 | **N**=60**Age** (mean yr): 49.3**Gender** (Male %): 23**Race/Ethnicity** (%): NR**Comorbidities**: NR**Criteria used to define RLS**IRLSSG**Baseline Severity**: moderate to severe, baseline mean IRLS score: 26.1**Previous RLS medication history**: NR but patients but had to complete a 2-week washout period off of the medication before becoming eligible**Iron Status**: NR | **Intervention:** Bupropion 150 mg**Comparator:** Placebo **A.** **Change in Disease Status and Impact**IRLS Scale Score**B. Quality of life**none**Subjective Sleep Quality**none**Definition of clinically significant Improvement:** NR**Adverse Effects Reported:** partially (withdrawals only) | **Assessment of Internal Validity**Sequence generation: adequateAllocation concealment: adequateBlinding of participants and personnel: yesIncomplete outcome data: no**Selective outcome reporting:** no**Reviewer Comments:** Improvement inIRLS Scale Score from baseline was significant (p=0.16) at week 3 but not week 6. Study was unable to recruit the target of 100 patients (leading possible type II error) |